EMA Authorised: Eviplera (emtricitabine;rilpivirine hydrochloride;tenofovir disoproxil fumarate) — Gilead Sciences International Ltd

View source ↗

Summary

The EMA authorised Eviplera, a fixed-dose combination of emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate, for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine (Emtricitabine)
• Rilpivirine hydrochloride (rilpivirine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Gilead Sciences International Ltd. Decision date: 27/11/2025